The popularity of Viagra initially sparked a period of growth for pharma, however recent developments present a uncertain outlook for those considering a stake. Generic alternatives are eroding revenue, and persistent patent challenges add more complexity to the landscape. While certain companies may still gain from related offerings, the overal… Read More